Mereo BioPharma (MREO) Depreciation & Amortization (CF) (2023 - 2026)

Mereo BioPharma (MREO) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $44000.0 the latest figure, recorded in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 15.79% year-over-year to $44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $323000.0 (up 17.03% YoY) and the FY2025 annual result came in at $200000.0, up 39.86% from the prior year.
• Depreciation & Amortization (CF) fell to $44000.0 in Q1 2026 per MREO's latest filing, from $79000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for MREO reached as high as $100000.0 in Q3 2023 and fell as low as $38000.0 in Q4 2024.
• A 4-year average of $71083.3 and a median of $75000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 46.48% — and 2025, when it jumped 107.89%.
• Year by year, Depreciation & Amortization (CF) stood at $71000.0 in 2023, then tumbled by 46.48% to $38000.0 in 2024, then soared by 107.89% to $79000.0 in 2025, then sank by 44.3% to $44000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $44000.0, $79000.0, and $100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.